Skip to main content
Erschienen in: Endocrine Pathology 4/2015

01.12.2015

PTEN and TP53 Mutations in Oncocytic Follicular Carcinoma

verfasst von: Shuanzeng Wei, Virginia A. LiVolsi, Kathleen T. Montone, Jennifer J. D. Morrissette, Zubair W. Baloch

Erschienen in: Endocrine Pathology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Oncocytic follicular carcinoma (OFC)/Hürthle cell carcinoma represents 3–4 % thyroid carcinomas and can be associated with more aggressive behavior and compromised survival compared to non-oncocytic thyroid carcinoma. In this study, we utilized targeted next-generation sequencing to investigate the molecular alterations in a heterogeneous group of clinically aggressive OFC. A total of 12 cases of OFC were included in this study. Targeted next-generation sequencing was performed using panels of 47 or 20 genes, which are frequently mutated in solid tumors. The case cohort comprised eight cases of angioinvasive OFC, two cases of poorly differentiated OFC, one case of OFC with anaplastic change, and one case of OFC with capsular invasion only. Five out of 12 cases (42 %) harbored TP53 mutation. PTEN mutations were also seen in three cases with TP53 mutation (25 %). Based on this study, TP53 and PTEN are possibly involved in the pathogenesis of OFC. Further studies on a larger case cohort are needed to further elucidate this mechanism and its effect on clinical behavior of these intriguing tumors.
Literatur
1.
Zurück zum Zitat DeLellis RA: Pathology and genetics of tumours of endocrine organs, vol. 8: IARC; 2004. DeLellis RA: Pathology and genetics of tumours of endocrine organs, vol. 8: IARC; 2004.
2.
Zurück zum Zitat Sobrinho-Simoes M, Eloy C, Magalhaes J, Lobo C, Amaro T: Follicular thyroid carcinoma. Mod Pathol 2011, 24 Suppl 2:S10-18.CrossRefPubMed Sobrinho-Simoes M, Eloy C, Magalhaes J, Lobo C, Amaro T: Follicular thyroid carcinoma. Mod Pathol 2011, 24 Suppl 2:S10-18.CrossRefPubMed
3.
Zurück zum Zitat Goffredo P, Roman SA, Sosa JA: Hurthle cell carcinoma: a population-level analysis of 3311 patients. Cancer 2013, 119(3):504–511.CrossRefPubMed Goffredo P, Roman SA, Sosa JA: Hurthle cell carcinoma: a population-level analysis of 3311 patients. Cancer 2013, 119(3):504–511.CrossRefPubMed
4.
Zurück zum Zitat Bai S, Baloch ZW, Samulski TD, Montone KT, LiVolsi VA: Poorly differentiated oncocytic (hurthle cell) follicular carcinoma: an institutional experience. Endocr Pathol 2015, 26(2):164–169.CrossRefPubMed Bai S, Baloch ZW, Samulski TD, Montone KT, LiVolsi VA: Poorly differentiated oncocytic (hurthle cell) follicular carcinoma: an institutional experience. Endocr Pathol 2015, 26(2):164–169.CrossRefPubMed
5.
Zurück zum Zitat Montone KT, Baloch ZW, LiVolsi VA: The thyroid Hurthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review. Arch Pathol Lab Med 2008, 132(8):1241–1250.PubMed Montone KT, Baloch ZW, LiVolsi VA: The thyroid Hurthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review. Arch Pathol Lab Med 2008, 132(8):1241–1250.PubMed
6.
Zurück zum Zitat Ghossein RA, Hiltzik DH, Carlson DL, Patel S, Shaha A, Shah JP, Tuttle RM, Singh B: Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases. Cancer 2006, 106(8):1669–1676.CrossRefPubMed Ghossein RA, Hiltzik DH, Carlson DL, Patel S, Shaha A, Shah JP, Tuttle RM, Singh B: Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases. Cancer 2006, 106(8):1669–1676.CrossRefPubMed
7.
Zurück zum Zitat Papotti M, Torchio B, Grassi L, Favero A, Bussolati G: Poorly differentiated oxyphilic (Hurthle cell) carcinomas of the thyroid. Am J Surg Pathol 1996, 20(6):686–694.CrossRefPubMed Papotti M, Torchio B, Grassi L, Favero A, Bussolati G: Poorly differentiated oxyphilic (Hurthle cell) carcinomas of the thyroid. Am J Surg Pathol 1996, 20(6):686–694.CrossRefPubMed
8.
Zurück zum Zitat Hunt JL, Tometsko M, LiVolsi VA, Swalsky P, Finkelstein SD, Barnes EL: Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am J Surg Pathol 2003, 27(12):1559–1564.CrossRefPubMed Hunt JL, Tometsko M, LiVolsi VA, Swalsky P, Finkelstein SD, Barnes EL: Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am J Surg Pathol 2003, 27(12):1559–1564.CrossRefPubMed
9.
Zurück zum Zitat Okon K, Wierzchowski W, Jablonska E, Wojcik P, Steczko A: Anaplastic, sarcomatoid carcinoma of the thyroid originating from a Hurthle cell tumor. Pol J Pathol 2003, 54(4):277–281.PubMed Okon K, Wierzchowski W, Jablonska E, Wojcik P, Steczko A: Anaplastic, sarcomatoid carcinoma of the thyroid originating from a Hurthle cell tumor. Pol J Pathol 2003, 54(4):277–281.PubMed
10.
Zurück zum Zitat Parameswaran R, Brooks S, Sadler GP: Molecular pathogenesis of follicular cell derived thyroid cancers. Int J Surg 2010, 8(3):186–193.CrossRefPubMed Parameswaran R, Brooks S, Sadler GP: Molecular pathogenesis of follicular cell derived thyroid cancers. Int J Surg 2010, 8(3):186–193.CrossRefPubMed
11.
Zurück zum Zitat Ganly I, Ricarte Filho J, Eng S, Ghossein R, Morris LG, Liang Y, Socci N, Kannan K, Mo Q, Fagin JA et al.: Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab 2013, 98(5):E962-972.CrossRefPubMed Ganly I, Ricarte Filho J, Eng S, Ghossein R, Morris LG, Liang Y, Socci N, Kannan K, Mo Q, Fagin JA et al.: Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab 2013, 98(5):E962-972.CrossRefPubMed
12.
Zurück zum Zitat Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M et al.: Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 2007, 31(8):1256–1264.CrossRefPubMed Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M et al.: Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 2007, 31(8):1256–1264.CrossRefPubMed
13.
Zurück zum Zitat Maximo V, Lima J, Prazeres H, Soares P, Sobrinho-Simoes M: The biology and the genetics of Hurthle cell tumors of the thyroid. Endocr Relat Cancer 2012, 19(4):R131-147.CrossRefPubMed Maximo V, Lima J, Prazeres H, Soares P, Sobrinho-Simoes M: The biology and the genetics of Hurthle cell tumors of the thyroid. Endocr Relat Cancer 2012, 19(4):R131-147.CrossRefPubMed
14.
Zurück zum Zitat Maximo V, Sobrinho-Simoes M: Mitochondrial DNA 'common' deletion in Hurthle cell lesions of the thyroid. J Pathol 2000, 192(4):561–562.CrossRefPubMed Maximo V, Sobrinho-Simoes M: Mitochondrial DNA 'common' deletion in Hurthle cell lesions of the thyroid. J Pathol 2000, 192(4):561–562.CrossRefPubMed
15.
Zurück zum Zitat Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simoes M: Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am J Pathol 2002, 160(5):1857–1865.PubMedCentralCrossRefPubMed Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simoes M: Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am J Pathol 2002, 160(5):1857–1865.PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Maximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, Amaro T, Barbosa AP, Preto A, Harach HR et al.: Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer 2005, 92(10):1892–1898.PubMedCentralCrossRefPubMed Maximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, Amaro T, Barbosa AP, Preto A, Harach HR et al.: Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer 2005, 92(10):1892–1898.PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Nikiforov YE, Nikiforova MN: Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011, 7(10):569–580.CrossRefPubMed Nikiforov YE, Nikiforova MN: Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011, 7(10):569–580.CrossRefPubMed
18.
Zurück zum Zitat Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, 2nd, Tallini G, Kroll TG, Nikiforov YE: RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003, 88(5):2318–2326.CrossRefPubMed Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, 2nd, Tallini G, Kroll TG, Nikiforov YE: RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003, 88(5):2318–2326.CrossRefPubMed
20.
Zurück zum Zitat Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S, Cognetti F et al.: PTEN: Multiple Functions in Human Malignant Tumors. Front Oncol 2015, 5:24.PubMedCentralCrossRefPubMed Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S, Cognetti F et al.: PTEN: Multiple Functions in Human Malignant Tumors. Front Oncol 2015, 5:24.PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK, Xing M: Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 2008, 93(8):3106–3116.CrossRefPubMed Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK, Xing M: Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 2008, 93(8):3106–3116.CrossRefPubMed
22.
Zurück zum Zitat Malaguarnera R, Vella V, Vigneri R, Frasca F: p53 family proteins in thyroid cancer. Endocr Relat Cancer 2007, 14(1):43–60.CrossRefPubMed Malaguarnera R, Vella V, Vigneri R, Frasca F: p53 family proteins in thyroid cancer. Endocr Relat Cancer 2007, 14(1):43–60.CrossRefPubMed
23.
Zurück zum Zitat Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE: Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab 2013, 98(11):E1852-1860.PubMedCentralCrossRefPubMed Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE: Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab 2013, 98(11):E1852-1860.PubMedCentralCrossRefPubMed
24.
Zurück zum Zitat Harach HR, Soubeyran I, Brown A, Bonneau D, Longy M: Thyroid pathologic findings in patients with Cowden disease. Ann Diagn Pathol 1999, 3(6):331–340.CrossRefPubMed Harach HR, Soubeyran I, Brown A, Bonneau D, Longy M: Thyroid pathologic findings in patients with Cowden disease. Ann Diagn Pathol 1999, 3(6):331–340.CrossRefPubMed
25.
Zurück zum Zitat Pradella LM, Zuntini R, Magini P, Ceccarelli C, Neri I, Cerasoli S, Graziano C, Gasparre G, Turchetti D: Two distinct thyroid tumours in a patient with Cowden syndrome carrying both a 10q23 and a mitochondrial DNA germline deletion. J Med Genet 2011, 48(11):779–782.CrossRefPubMed Pradella LM, Zuntini R, Magini P, Ceccarelli C, Neri I, Cerasoli S, Graziano C, Gasparre G, Turchetti D: Two distinct thyroid tumours in a patient with Cowden syndrome carrying both a 10q23 and a mitochondrial DNA germline deletion. J Med Genet 2011, 48(11):779–782.CrossRefPubMed
Metadaten
Titel
PTEN and TP53 Mutations in Oncocytic Follicular Carcinoma
verfasst von
Shuanzeng Wei
Virginia A. LiVolsi
Kathleen T. Montone
Jennifer J. D. Morrissette
Zubair W. Baloch
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Endocrine Pathology / Ausgabe 4/2015
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-015-9403-6

Weitere Artikel der Ausgabe 4/2015

Endocrine Pathology 4/2015 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …